Latest filing published 24 Jul 2026 for Shanghai Bio-heart Biological Technology Co., Ltd. - B -H Sh, €2,625. Read the official filing
Across 21 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Wang Philip Li, listed as chief executive, has filed trades across 2 companies (mainly through HKEX), most often in Shanghai Bio-heart Biological Technology Co., Ltd. - B -H Sh and Shanghai Bio-heart Biological Technology Co., Ltd. - B. The record holds 66 filings, for trades running from 14 April 2026 to 24 July 2026.
Purchases make up the whole of the open-market record (66 purchases, €1.2M). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
In size, the median ticket on the buying side is €3,453. Relative to company size, the median is 0.0000% of market cap (44 purchases with a known value). None of the 66 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The newest entry dates from 24 July 2026: an open-market purchase of €2,735, in Shanghai Bio-heart Biological Technology Co., Ltd. - B -H Sh. The median gap between trade and publication is zero days: most filings appear on the same day. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 66 declarations